Access cutting-edge i cannot determine the primary medical condition from the provided information. the study title mentions "regeneron aa multicenter (dupilumab)" but "aa" is too ambiguous, and the conditions field only lists drug names rather than medical conditions. the brief summary field appears to be incomplete (showing only a localhost url). without additional context about what condition dupilumab is being tested for in this specific trial, i cannot provide the patient-facing medical condition. treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this New York location
Access i cannot determine the primary medical condition from the provided information. the study title mentions "regeneron aa multicenter (dupilumab)" but "aa" is too ambiguous, and the conditions field only lists drug names rather than medical conditions. the brief summary field appears to be incomplete (showing only a localhost url). without additional context about what condition dupilumab is being tested for in this specific trial, i cannot provide the patient-facing medical condition. specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related i cannot determine the primary medical condition from the provided information. the study title mentions "regeneron aa multicenter (dupilumab)" but "aa" is too ambiguous, and the conditions field only lists drug names rather than medical conditions. the brief summary field appears to be incomplete (showing only a localhost url). without additional context about what condition dupilumab is being tested for in this specific trial, i cannot provide the patient-facing medical condition. treatment provided free
Check if you qualify for this i cannot determine the primary medical condition from the provided information. the study title mentions "regeneron aa multicenter (dupilumab)" but "aa" is too ambiguous, and the conditions field only lists drug names rather than medical conditions. the brief summary field appears to be incomplete (showing only a localhost url). without additional context about what condition dupilumab is being tested for in this specific trial, i cannot provide the patient-facing medical condition. clinical trial in New York, NY
No-Cost Study Care
Local to New York
Convenient for NY residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers through Week 48. AA subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥ 200 and/or have personal and/or familial history of
Sponsor: Emma Guttman
Yes, this clinical trial (NCT05551793) has an active research site in New York, NY that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for i cannot determine the primary medical condition from the provided information. the study title mentions "regeneron aa multicenter (dupilumab)" but "aa" is too ambiguous, and the conditions field only lists drug names rather than medical conditions. the brief summary field appears to be incomplete (showing only a localhost url). without additional context about what condition dupilumab is being tested for in this specific trial, i cannot provide the patient-facing medical condition. treatment options in New York, NY, this clinical trial (NCT05551793) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced i cannot determine the primary medical condition from the provided information. the study title mentions "regeneron aa multicenter (dupilumab)" but "aa" is too ambiguous, and the conditions field only lists drug names rather than medical conditions. the brief summary field appears to be incomplete (showing only a localhost url). without additional context about what condition dupilumab is being tested for in this specific trial, i cannot provide the patient-facing medical condition. specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all i cannot determine the primary medical condition from the provided information. the study title mentions "regeneron aa multicenter (dupilumab)" but "aa" is too ambiguous, and the conditions field only lists drug names rather than medical conditions. the brief summary field appears to be incomplete (showing only a localhost url). without additional context about what condition dupilumab is being tested for in this specific trial, i cannot provide the patient-facing medical condition. clinical trials near you to find additional studies recruiting in your area.
See all multiple myeloma clinical trials recruiting in New York — not just this study.
Browse Multiple Myeloma Trials in New York →